Market Place
Sourcing Support
Sarepta Therapeutics to Report Q1 2026 Financial Results
22 Apr 2026 //
BUSINESSWIRE
Sarepta Overcomes Gene Therapy Setback With Early RNA Therapy
26 Mar 2026 //
BIOSPACE
Sarepta`s Big Bet On Arrowhead`s Sirna Assets Yields Early Data
25 Mar 2026 //
FIERCE BIOTECH
Sarepta To Share siRNA Data In FSHD1, DM1
24 Mar 2026 //
BUSINESSWIRE
Sarepta Therapeutics Presents At TD Cowen Health Care Conference
24 Feb 2026 //
BUSINESSWIRE
REGENXBIO Wins Gene Therapy Patent Battle Against Sarepta
23 Feb 2026 //
BIOSPACE
Sarepta Presents at 44th J.P. Morgan Healthcare Conference
05 Jan 2026 //
BUSINESSWIRE
Arrowhead Pharma Receives $200M Milestone Payment From Sarepta
24 Nov 2025 //
BUSINESSWIRE
Sarepta Reveals Q3 2025 Financials, Confirms ESSENCE Study
03 Nov 2025 //
BUSINESSWIRE
Krystal Secures FDA`s Second Platform Designation Following
15 Oct 2025 //
BIOSPACE
Sarepta Advances LGMD Gene Therapy With Promising Data
15 Oct 2025 //
BIOSPACE
Sarepta Shares More Elevidys Safety Data
19 Aug 2025 //
FIERCE PHARMA
Sarepta Provides New Elevidys Safety Data, Zero Ambulatory Dies
18 Aug 2025 //
BIOSPACE
Sarepta Sells 9M Arrowhead Shares for $174M
13 Aug 2025 //
FIERCE BIOTECH
Arrowhead Redeems $50M Stock, Gets $50M Sarepta Milestone
13 Aug 2025 //
BUSINESSWIRE
Sarepta Advances siRNA Collaboration, Sells Arrowhead Equity
13 Aug 2025 //
BUSINESSWIRE
Arrowhead Emerges as RNAi Knight Amid Sarepta `Downdraft`
12 Aug 2025 //
BIOSPACE
Sarepta Beats Q2 Estimates Despite Safety Drama, Elevidys Sales
07 Aug 2025 //
BIOSPACE
Untangling Sarepta`s Gene Therapy Fallout
01 Aug 2025 //
FIERCE PHARMA
FDA Reverses Stance on Sarepta`s DMD Gene Therapy Elevidys
28 Jul 2025 //
FIERCE PHARMA
FDA Reverses on Sarepta`s DMD Gene Therapy Elevidys
28 Jul 2025 //
FIERCE BIOTECH
Arrowhead Hits $100M Milestone, Awaits Sarepta Payment
28 Jul 2025 //
FIERCE BIOTECH
Sarepta’s Future Uncertain as FDA Eyes New Study for Elevidys
25 Jul 2025 //
BIOSPACE
Arrowhead Reassures investors about pact with troubled Sarepta
24 Jul 2025 //
PRESS RELEASE
Sarepta to Pause Elevidys Gene Therapy Shipments in Us
22 Jul 2025 //
REUTERS
Sarepta Faces New Scrutiny After 3rd Patient Death
19 Jul 2025 //
FIERCE BIOTECH
FDA Mulls Halting Elevidys Shipments, Sarepta Stock Plunges
18 Jul 2025 //
BIOSPACE
Sarepta Therapeutics Provides Statement on Elevidys
18 Jul 2025 //
BUSINESSWIRE
Sarepta Up 18% After Business Overhaul as Analysts Optimistic
18 Jul 2025 //
BIOSPACE
Sarepta to Cut 500 Jobs, Add Black-Box Warning on Gene Therapy
17 Jul 2025 //
REUTERS
FDA Investigates Patient Deaths with Sarepta`s Gene Therapy
25 Jun 2025 //
FDA
FDA Awards Platform Status to Sarepta SRP-9003 Gene Vector
04 Jun 2025 //
BUSINESSWIRE
Sarepta Shows Strong EMBARK Data in Gene Therapy Study
16 May 2025 //
BUSINESSWIRE
Sarepta Therapeutics Shares New Endeavor Results in 2-Year-Olds
16 May 2025 //
BUSINESSWIRE
Sarepta sees delays in treatment after Elevidys death report
08 May 2025 //
FIERCE PHARMA
Sarepta halts gene therapy studies for muscle disorder
05 Apr 2025 //
REUTERS
Patient dies after receiving Sarepta’s DMD gene therapy Elevidys
19 Mar 2025 //
FIERCE PHARMA
Sarepta Therapeutics Reports Q4, Full-Year 2024 Net Revenue
13 Jan 2025 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
31 Dec 2024 //
BUSINESSWIRE
Sarepta Completes Enrollment in SRP-9003 Ph 3 Study for LGMD2E/R4
18 Dec 2024 //
BUSINESSWIRE
Sarepta Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
29 Nov 2024 //
BUSINESSWIRE
Sarepta, Arrowhead ink $1B-plus deal for seven programs
27 Nov 2024 //
FIERCE BIOTECH
Sarepta axes late-phase DMD drug over safety signal
08 Nov 2024 //
FIERCE BIOTECH
Sarepta Therapeutics Announces Q3 2024 Results & Developments
06 Nov 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Rule
31 Oct 2024 //
BUSINESSWIRE
Sarepta Therapeutics Q3 2024 Financial Results Announcement
23 Oct 2024 //
BUSINESSWIRE
Sarepta To Present At World Muscle Society Congress
26 Sep 2024 //
BUSINESSWIRE
Sarepta Therapeutics Announces 2024-25 Route 79 Duchenne Scholarship Recipients
05 Sep 2024 //
BUSINESSWIRE
Sarepta Seeks Label Expansion, Bigger Market for DMD Gene Therapy
08 May 2024 //
BIOSPACE
Gene Therapy Pioneer Mendell Named To TIME100 Health List
03 May 2024 //
BUSINESSWIRE
ICER pushes back on FDA`s potential of Sarepta`s gene therapy to full approval
02 May 2024 //
ENDPTS
FDA decision on Sarepta’s Duchenne gene therapy could come earlier than expected
01 May 2024 //
ENDPTS
Elevidys gains steam amid Sarepta`s efforts to widen FDA label
29 Feb 2024 //
FIERCE PHARMA
Internal documents shed new light on Sarepta FDA decision
27 Feb 2024 //
ENDPTS
Sarepta Announces Positive Data from Part B of MOMENTUM, a Phase 2 of SRP-5051
29 Jan 2024 //
BUSINESSWIRE
Sarepta Announces Positive Data from Phase 2 Study of SRP-5051
29 Jan 2024 //
PRESS RELEASE
Sarepta Initiates Screening in EMERGENE, a Phase 3 Clinical Study of SRP-9003
16 Jan 2024 //
BUSINESSWIRE
FDA`s CBER chief hints at expanding Sarepta`s gene therapy label
10 Jan 2024 //
ENDPTS
Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label
22 Dec 2023 //
BUSINESSWIRE
Sarepta`s Elevidys off to strong start despite label restriction
02 Nov 2023 //
FIERCE PHARMA
